About UltiMed, Inc. UltiMed is headquartered in St. Paul, Minnesota and owns and operates state-of-the-art medical device manufacturing facilities in the U.S. and abroad. The Company also has a wide range of global business partners bringing a broad spectrum of medical products to customers around the world.
The History of UltiMed. UltiMed has been in business since 1988, beginning with their first medical device manufacturing facility. In the mid-1990’s, UltiMed refined its focus and concentrated on the growing diabetic market, manufacturing insulin syringes and related medical products which are sold through retail pharmacies and mail order providers. The Company also specializes in manufacturing high quality injection devices sold through various channels in the hospital and veterinary market.
In addition to providing customers the highest quality products, in the late 1990’s, the Company pushed forward an aggressive initiative to reinvent the existing retail insulin syringe product for in- home injections. The Company noticed that with the increasing incidence of diseases that require injections outside a typical medical facility and the increase in infectious diseases transferred through used needles, improper syringe disposal was becoming a growing epidemic. The syringe disposal issue adversely affects everyone: family members, friends, co-workers, children, trash collectors, etc.
Each year over 2 billion syringes are disposed of incorrectly. The estimated cost of needle stick injuries is approximately $1.6 billion per year. Additionally, the impact of contracting diseases as a result of syringes disposed of incorrectly through the trash stream is tragic. As a result, UltiMed developed the proprietary UltiGuard™, packaging insulin syringes within a dispenser and disposal container that is LESS EXPENSIVE! than the leading brand insulin syringe. UltiMed's unique packaging concept provides more to customers and the community at a lower cost relative to the branded equivalent. After years of research and development, the UltiGuard™ insulin syringe line was introduced.
In conjunction with the introduction of the UltiGuard™, The Company opened their second state-of-the-art manufacturing facility in the U.S. This facility has the capability of producing the highest quality insulin syringes in the world and is ISO certified and FDA inspected.
UltiMed has continued to progress rapidly by adding new members to the management team and board of directors. The Company has increased manufacturing capabilities, distribution networks, product breadth and has launched the most aggressive private label program in the market.